Since 2016, numerous of innovative drugs from the top R&D directions, mostly represented by selective cancer targeting drugs and immuno-oncology drugs, have successfuly entered the clinical trials and further been approved for clinical practice as a treatment of solid tumors, lung cancer, breast cancer, lymphoma, liver cancer and leukemia etc. Since its establishment, Proswell Medical Development Center has focused on bringing together international standard, local regulations and knowledge about real clinical practice needs to conduct clinical trials for new drugs in the field of oncology in cooperation with oncology national level key opinion leaders and local and overseas Sponsors. Such joint effort resulted in market authorization granted for numerous innovative drugs, therefore delivered cutting-edge treatment methods to the patients in need. Even during the outbreak period of COVID-19, Proswell achievements and contribution into public healthcare sector was demonstrated by the augmentation of the number of new oncology drug clinical trials.

Proswell Medical Development Center has established and continue to maintain long-term and stable cooperative relationship with best in a country cancer treatment hospitals. Hundreds of clinical trials of each phase have been completed through the years, and 13 innovative drugs have successfully been marketed in China. Our rich clinical trial experience is a useful tool for our sponsors to explore new opportunity for applications of new investigational drugs and to design clinical trial strategy with accuracy, which includes precise benchmarking of oncology treatment protocols and subject screening methods to develop a complete procedures and concepts of risk management and risk control and project management preventive measures for oncology clinical trials. That resulted in reduction of all kinds of risks and improved efficiency. Our dedicated oncology team are rigorous thinkers with creative eye on doing professional things, where the clinical experience meets fundamental pharmaceutical and medical knowledge to consolidate and dedicate all our efforts to successfully complete oncology clinical trials.

Our oncology experience includes but are not limited to solid tumors, breast cancer, lymphoma, liver cancer, leukemia, gastric cancer, glioma, myeloma, etc. We are experienced in conducting trials for different types of innovative drugs, biosimilar and generic drugs. The drug mechanisms of action are mostly realized through cytotoxicity caused by selective cancer targeting drugs and immuno-oncology drugs, for instance, programmed death protein 1 (PD-1), epidermal growth factor receptor (EGFR), programmed death ligand 1 (PD-L1), human epidermal growth factor receptor 2 (HR-2), etc.